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vivo and also the fragility of the organism during processing
in the laboratory.
This is the first case report of disseminated S. vasiformis
infection with endocardial and myocardial involvement con-
firmed by postmortem examination.
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Prevalence and Clinical Significance of Splenomegaly
in Asymptomatic Human Immunodeficiency Virus
Type 1–Infected Adults
In a prospective cohort study of 70 consecutive, asymp-
tomatic human immunodeficiency virus type 1 (HIV-
1)–infected adults, splenomegaly was found by physical
examination in 23% of patients and by ultrasound in 66%.
Patients with concomitant liver disease had a higher prev-
alence of splenomegaly (RR 1.84; ). During a 1-P ! .001
year follow-up of 66 patients, splenomegaly at enrollment
was not predictive of any clinical event, and splenomegaly
was not associated with a higher risk of developing AIDS
during a median follow-up of 6.1 years.
Splenomegaly is a frequent finding among HIV-infected
adults [1, 2]. It has been found in up to 70% in a postmortem
study [3]. However, little is known about the prevalence and
clinical significance of this finding in asymptomatic patients.
Previous studies have often been biased by referral and included
patients in different stages of HIV infection [1, 4–6]. Therefore,
we conducted a prospective observational study among asymp-
tomatic HIV-1–infected outpatients.
Our outpatient clinic is one of the 7 centers of the Swiss HIV
Cohort Study (SHCS). Within this community-based cohort
study, HIV-infected individuals aged >16 years are followed at
6-month intervals according to standardized criteria that have
been described elsewhere [7].
Patients were eligible for the present study if they were in
Centers for Disease Control and Prevention (CDC) stage A [8]
or if they had thrombocytopenia as the only HIV-associated
clinical manifestation. During a 4-month period in 1993, all
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consecutive patients in CDC stage A underwent ultrasono-
graphic evaluation of spleen size. Sonography was performed
only once. Seventy-six patients were eligible, of which 70 were
analyzed (5 did not consent to the examination, and 1 patient
had had a splenectomy).
Patients underwent physical examination by their physicians
(who were aware of the study) and underwent ultrasonography
the same day. Sonography was always done by the same ex-
aminer, who was not aware of the results of the clinical ex-
amination. Clinical splenomegaly was present if the spleen was
palpable. Splenomegaly was defined by ultrasound as a spleen
with a long axis >120 mm [9]. Sociodemographic data and
laboratory values were extracted from the SHCS database and
from patients’ charts. Clinical events were recorded prospec-
tively for 1 year after the examination to evaluate the clinical
importance of splenomegaly.
Of the 70 patients in our cohort, 50 (71%) were male and 20
were female; the median age was 31 years (range, 21–51 years).
With respect to the mode of HIV-1 transmission, 26 patients
were men who have sex with men, 22 were heterosexual, and
20 were injection drug users; 2 were infected by other modes
of transmission. Peripheral lymphadenopathy was found in 40
patients (58%). The median CD4 cell count was 417 cells/mL
(range, 35–890 cells/mL). Seven patients (10%) had platelet
counts cells/L. Twenty-nine patients (41%) had liver9! 125 3 10
disease, defined as positive hepatitis B surface antigen, positive
hepatitis C serology, or alanine aminotransferase (ALT) levels
above the upper normal limit; 24 (83%) of those 29 had positive
serology for hepatitis C.
Statistical analyses included single table analysis, unpaired t
test and univariate regression analysis, Kaplan-Meier estimates,
and Cox’s regression analysis; all of these were performed using
Epi Info 6 (CDC; Atlanta, GA) and Stata 6 software (Stata,
College Station, TX).
Splenomegaly was found in 14 patients (23%) by clinical
examination and in 46 (66%) by ultrasound examination (figure
1). Median spleen size was 125 mm (range, 92–197 mm). In 2
of the 14 patients with clinical splenomegaly, this finding was
not confirmed by ultrasound. An enlarged spleen was suspected
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Figure 1. Histogram of long spleen axis (spleen length) measured
by ultrasound in 70 consecutive patients who were infected with HIV
but were asymptomatic.
Figure 2. Box plot of measurements of the long axis of the spleen
in patients without (left) and with (right) palpable spleen. Horizontal
lines indicate the 25th, 50th (median), and 75 percentiles; vertical brack-
ets indicate the 10th and 90th percentiles, dots (v) indicate values below
the 10th or above the 90th percentiles.
clinically only in 12 (26%) of 46 patients with splenomegaly by
using ultrasound.
Spleen size in patients without palpable spleens was signifi-
cantly smaller than that in patients with palpable spleens (mean
spleen , mm vs. mm;length 5 SD 120 5 13 140 5 25 P =
). A box plot of the spleen size for the two groups is shown.001
in figure 2.
The prevalence of splenomegaly was higher in patients with
liver disease (90%) than in those without it (48%; RR, 1.84;
95% CI, 1.3–2.6; ). Among patients with a positiveP ! .001
serology for hepatitis C, splenomegaly was found in 22 (92%)
of 24. Presence of peripheral lymphadenopathy was not asso-
ciated with splenomegaly (RR, 0.9; 95% CI, 0.6–1.3). Of the 7
patients with thrombocytopenia, 4 had splenomegaly (RR,
0.86; 95% CI, 0.4–1.7). There was no correlation between CD4
count and spleen size ( ; ).r = .03 P = .8
Four participants were lost to follow-up during the following
12 months. Of the remaining 66 patients (94%), 14 had pro-
gression of HIV-1 infection according to CDC criteria. Twelve
patients had a stage B event (candida stomatitis, 7 patients;
multisegmental herpes zoster, 2; oral hairy leukoplakia, 2; and
unexplained weight loss, 1). Two participants progressed to
stage C (1 had recurrent episodes of bacterial pneumonia and
1 had Pneumocystis carinii pneumonia).
Patients with progression of HIV-infection during the 1-year
follow-up did not have a higher prevalence of splenomegaly
(RR, 1.1; 95% CI, 0.72–1.55; ), but had lower CD4 cellP = 1.0
counts (median 325 cells/mL vs. 460 cells/mL, ) at studyP = .01
entry.
Sixty-six patients were followed further within the framework
of the SHCS, and AIDS-defining events and death were re-
corded. Data were assessed at the last follow-up visit at our
center. Median follow-up was 74 months (interquartile range,
60–76 months). Seven patients died during the extended follow-
up; 6 of those 7 had had splenomegaly at baseline. The causes
of death were AIDS related (4 patients), suicide (1), narcotic
drug overdose (1), and subarachnoid hemorrhage (1). Fourteen
patients progressed to AIDS, of whom 12 had had spleno-
megaly at baseline. One patient, whose spleen was 130 mm long
at enrollment, had a non-Hodgkin’s lymphoma diagnosed 29
months later.
Kaplan-Meier estimates for AIDS-free survival did not show
a significant difference between patients with or without sple-
nomegaly at baseline (log rank test, ). In a Cox’s re-P = .12
gression analysis that included baseline CD4 count, age, and
splenomegaly, the hazard ratio for patients with splenomegaly
for developing AIDS was not significantly different than it was
for patients without splenomegaly at baseline (hazard ratio 3.0;
95% CI, 0.66–13.5; ).P = .15
In summary, we found splenomegaly (defined as a spleen with
a long axis >120 mm) in two-thirds of consecutive asympto-
matic HIV-1 infected patients in our study. The sociodemo-
graphic characteristics of study participants were similar to
those of asymptomatic HIV-infected patients seen in our clinic,
and to the entire asymptomatic SHCS population, as well as
to the asymptomatic HIV-1–infected patients in Switzerland
[10]. Thus, our study sample appeared to be representative of
asymptomatic HIV-1–infected patients in Switzerland and less
biased by referral than were previous study populations that
addressed the frequency of splenomegaly in HIV-1–infected
adults.
Our findings confirm the observations made by others [11],
that clinical examination alone is a poorly sensitive, but rea-
sonably specific method for detection of moderate splenomeg-
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aly [12]. The prevalence of sonographic splenomegaly was
higher in patients with liver disease, which was mostly due to
chronic hepatitis C (HCV) infection in our population. Chronic
HCV infection without HIV infection can lead to isolated sple-
nomegaly in about one-fourth of the patients [13], whereas it
was a nearly universal feature in our patients who were co-
infected with HIV-1 and HCV. In contrast, splenomegaly was
not associated with peripheral lymphadenopathy or with grade
of immunodeficiency, as measured by CD4 cell counts. Throm-
bocytopenia was not definitively associated with splenomegaly,
but the number of patients with low platelet counts in our study
was too small to draw definitive conclusions.
To date, the clinical importance of splenomegaly in asymp-
tomatic HIV-1–infected individuals has remained unclear. We
were able to follow 190% of the patients for at least 1 year.
Splenomegaly was not associated with progression of HIV in-
fection. Furthermore, during a 1-year follow-up period no pa-
tient developed HIV-associated opportunistic infections or ma-
lignancies or other non-HIV–related diseases known to be
typically preceded by or associated with splenomegaly.
A great concern when splenomegaly is found is that it might
be non-Hodgkin’s lymphoma. One patient in our series devel-
oped this disease 29 months after enrollment in the study. It is
unlikely that the moderately enlarged spleen at enrollment was
an early manifestation of this malignant disease. On the basis
of our data, it does not seem warranted to perform invasive
studies to rule out non-Hodgkin’s lymphoma in otherwise
asymptomatic HIV-infected persons with splenomegaly.
During a median follow-up of 16 years, progression to AIDS
was not associated with splenomegaly at baseline. Plasma HIV
RNA levels were not available at baseline. Therefore, we could
not analyze an association of splenomegaly with the most im-
portant prognostic marker [14] and could not correct for it in
our Cox’s regression analysis. Our population was too small
to find even moderate associations between splenomegaly and
progression to AIDS. Furthermore, the follow-up was extended
into a period where combination antiretroviral therapies be-
came available and these agents had a major influence on mor-
bidity and mortality in HIV-infected persons [15]. Therefore,
we were not able to study the natural history of HIV infection
with regard to splenomegaly in our cohort.
Extensive evaluation, beyond a search for hepatitis C infec-
tion, is not warranted in asymptomatic HIV-1–infected indi-
viduals with an incidental finding of splenomegaly. Conversely,
given the high prevalence of splenomegaly in asymptomatic
HIV-infected adults, HIV infection should be part of the dif-
ferential diagnosis of otherwise unexplained splenomegaly in
adults with unknown serostatus of HIV infection.
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